News

Katzenell Dimant /

KD Represents Kitov in Acquisition of TyrNovo

   

tyrnovo_7b90ebb0-9ebd-11e5-9a16-a7b5708cc3a7

We are proud of our client Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical drug development company, for expanding their pipeline through the acquisition of a majority stake in TyrNovo Ltd., a privately held developer of novel small molecules in the immuno-oncology therapeutic field.

Read the press on TheMarker, PRNewswire, Genetic Engineering & Biotechnology News

icon14_1

See some other notable transactions lead by our Hi-Tech & Life Sciences practice

Share:

read more in: